Obesity
Conditions
Interventions
Intervention group:Highly bioavailable curcumin preparation (Pharnod curcumin capsules), 400 mg/capsule/day, used continuously for 3 months
Sponsors
The First People's Hospital of Xiangtan City
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) Age 18–65 years (including cut-off value). There is no limit to men and women. 2) Semaglutide weight loss treatment has been completed and has lost at least 10% of the basal body weight compared with the pre-treatment treatment. 3) Those who plan to stop semaglutide or stop using it for less than 5 weeks. 4) Willing to receive uniform standard management during the study period and avoid using other weight loss drugs, weight loss supplements, or other interventions that may significantly affect body weight. 5) Able to understand the content of the study and voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: Study subjects who meet any of the following exclusion criteria cannot participate in this study: 1) Known allergy to curcumin or ginger products, or clear contraindications. 2) Are using strong anticoagulant medications, or have a clear risk of drug interactions that are judged by the investigator to be unsuitable for curcumin. 3) Severe abnormal liver function, severe renal function abnormalities, or other serious organic diseases that the investigator believes are not suitable for participation in this study. 4) Presence of definite endocrine disorders that may cause obesity or weight changes, such as Cushing's syndrome, significant thyroid dysfunction, pituitary or hypothalamic disease. 5) Previous serious cardiovascular and cerebrovascular events, tumor history, severe gastrointestinal diseases, or major gastrointestinal surgery. 6) Pregnant or lactating women, or those who have a definite pregnancy plan during the study. 7) Frequent adjustment of concomitant medication within 8 weeks before the study, and it is expected that frequent adjustment will still be required during the study, which may significantly affect body weight or metabolic outcomes. 8) The investigator judges that he or she is unable to complete the visit, testing, and follow-up as planned, and other conditions that make him or her unsuitable for participating in this study. 9) Before formal enrollment, those whose body weight is rebounded by more than 20% of the total weight loss will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Weight; | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight;Body Fat Ratio;Body Fat Ratio;Waist circumference;Waist circumference;Hip circumference;Hip circumference;Muscle mass;Muscle mass;Fasting Blood Glucose;Fasting Blood Glucose;Fasting Insulin;Fasting Insulin;HbA1c;HbA1c;Cholesterol;Cholesterol;Triglyceride;Triglyceride;High-density lipoprotein;High-density lipoprotein;Low-density lipoprotein;Low-density lipoprotein; | — |
Countries
China
Contacts
Public ContactXie Genqing
The First People's Hospital of Xiangtan City
Outcome results
None listed